Targeting mitochondrial complexes for cancer therapy.
2/5 보강
TL;DR
The pathophysiology of CML and the development of TKI‐based treatments, including first‐, second‐, and third‐generation medicines, are thoroughly examined and the development of new therapeutic approaches is examined as a forward‐looking tactic to produce more profound and long‐lasting molecular responses.
OpenAlex 토픽 ·
Mitochondrial Function and Pathology
ATP Synthase and ATPases Research
Coenzyme Q10 studies and effects
The pathophysiology of CML and the development of TKI‐based treatments, including first‐, second‐, and third‐generation medicines, are thoroughly examined and the development of new therapeutic approa
APA
Alaa M.A. Osman, Alya A. Arabi (2026). Targeting mitochondrial complexes for cancer therapy.. Biochemical pharmacology, 247, 117695. https://doi.org/10.1016/j.bcp.2026.117695
MLA
Alaa M.A. Osman, et al.. "Targeting mitochondrial complexes for cancer therapy.." Biochemical pharmacology, vol. 247, 2026, pp. 117695.
PMID
41525932 ↗
Abstract 한글 요약
Mitochondrial Complexes I-IV in the Electron Transport Chain (ETC) are strategic targets for cancer treatment since they provide the energy and biosynthetic demands of cancer cells. This review covers in silico, in vitro, and in vivo findings related to the inhibition of ETC complexes in order to block cancer cell survival. It also includes computational docking studies that we performed to confirm the binding of literature-reported inhibitors to ETC complexes. This review also covers details about bioenergetic disruption as well as innovative therapeutic strategies based on the Oxidative Phosphorylation (OXPHOS) activity and the ETC dependencies in cancer cells. This review serves as a guide for the development of small molecules that target the ETC for cancer treatment.